CD8A and neoplasm: Furthermore, DEX‐CBX significantly increased natural killer T cells (5.7‐fold) and CD8+ T cells (3.9‐fold) as well as decreased M2 macrophages (59% reduction) over PBS treatment, resulting in a tumor suppression rate of 85.4%.